Pharma Co. Must Face Investor Suit Over Cancer Drug Study

By Sydney Price · January 23, 2024, 9:38 PM EST

Spectrum Pharmaceuticals must face a consolidated proposed securities class action alleging it misled investors about a lung cancer treatment drug study after a New York federal judge decided Tuesday that the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Christiansen, et al v. Spectrum Pharmaceuticals, Inc. et al

Case Number

Court

New York Southern

Nature of Suit

Securities/Commodities

Date Filed

December 05, 2022

Recent Articles By Sydney

May 15, 2024
UnitedHealth Concealed DOJ Merger Investigation, Suit Says
May 13, 2024
Biogen Investors Seek Class Cert. In Alzheimer's Drug Suit
May 08, 2024
Shockwave Medical Investor Challenges $13B Deal With J&J
May 07, 2024
Pharma Co. Falsely Touted Obesity Drug Results, Suit Claims
May 06, 2024
Judge Trims ESOP Valuation Suit Against Healthcare Co.
April 29, 2024
AI Pharma Co. Sued By Investor Over Handling Of Fired CEO
April 23, 2024
GoodRx Hid Revenue Reliance On Kroger, Suit Claims
April 03, 2024
Healthcare Company Hid Rising Costs Before IPO, Suit Says
April 01, 2024
Pharma Co. Beats Investor Suit Over Wrinkle Drug Approval
March 22, 2024
Pharma Co. Brass Overhyped ALS Drug Efficacy, Suit Says